198 related articles for article (PubMed ID: 26496320)
21. [Phase II randomized clinical trail of zoledronic acid in treating metastatic bone pain of malignancy].
Zhang G; Cai W; Zhou YF; Li PW; Gao YJ; Zhang Y; Wang SJ; Mao GG; Liu B
Ai Zheng; 2005 Dec; 24(12):1489-92. PubMed ID: 16351798
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Reed SD; Radeva JI; Glendenning GA; Coleman RE; Schulman KA
Am J Clin Oncol; 2005 Feb; 28(1):8-16. PubMed ID: 15685028
[TBL] [Abstract][Full Text] [Related]
23. Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study.
Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kim JH; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
BioDrugs; 2022 May; 36(3):381-392. PubMed ID: 35412221
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
25. Zoledronic acid: a new parenteral bisphosphonate.
Li EC; Davis LE
Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
[TBL] [Abstract][Full Text] [Related]
26. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
Caffo O
Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
[No Abstract] [Full Text] [Related]
27. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
Hortobagyi GN; Van Poznak C; Harker WG; Gradishar WJ; Chew H; Dakhil SR; Haley BB; Sauter N; Mohanlal R; Zheng M; Lipton A
JAMA Oncol; 2017 Jul; 3(7):906-912. PubMed ID: 28125763
[TBL] [Abstract][Full Text] [Related]
28. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
Lipton A
Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S14-20. PubMed ID: 17683649
[TBL] [Abstract][Full Text] [Related]
30. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Machado M; Cruz LS; Tannus G; Fonseca M
Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
[TBL] [Abstract][Full Text] [Related]
32. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
33. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.
DesHarnais Castel L; Bajwa K; Markle JP; Timbie JW; Zacker C; Schulman KA
Support Care Cancer; 2001 Oct; 9(7):545-51. PubMed ID: 11680835
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
Sanfilippo KM; Gage B; Luo S; Weilbaecher K; Tomasson M; Vij R; Colditz G; Carson K
Leuk Lymphoma; 2015 Mar; 56(3):615-21. PubMed ID: 24844358
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
36. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Lipton A; Fizazi K; Stopeck AT; Henry DH; Brown JE; Yardley DA; Richardson GE; Siena S; Maroto P; Clemens M; Bilynskyy B; Charu V; Beuzeboc P; Rader M; Viniegra M; Saad F; Ke C; Braun A; Jun S
Eur J Cancer; 2012 Nov; 48(16):3082-92. PubMed ID: 22975218
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
38. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.
Coleman RE; Seaman JJ
Semin Oncol; 2001 Apr; 28(2 Suppl 6):11-6. PubMed ID: 11346860
[TBL] [Abstract][Full Text] [Related]
39. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Amadori D; Aglietta M; Alessi B; Gianni L; Ibrahim T; Farina G; Gaion F; Bertoldo F; Santini D; Rondena R; Bogani P; Ripamonti CI
Lancet Oncol; 2013 Jun; 14(7):663-70. PubMed ID: 23684411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
